Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Epithelial Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Morphology
Epithelial Neoplasm

Cancer Family

Epithelial Neoplasm

CI-CAN-00000016Explore in graph →

Non-malignant7,525 active trials118 approved drugs1,152 evidence items

NCIt: C3709

Overview
Statistics
Survival
Genomics314
Variants & evidence1152
Drugs206
Trials26878
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (916)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 126–150 of 916 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Association studies of Fcγ receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831.
· Cancer Immunol Res · 2014 · PMID 24989892 · validated civic_curation pubmed
Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer.
· Am J Obstet Gynecol · 2005 · PMID 15746676 · validated civic_curation pubmed
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
· N Engl J Med · 2006 · PMID 17192538 · validated civic_curation pubmed
Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.
· J Clin Oncol · 2009 · PMID 19289619 · validated civic_curation pubmed
Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis.
· J Thorac Oncol · 2016 · PMID 26899019 · validated civic_curation pubmed
Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.
· Lancet Oncol · 2014 · PMID 24793816 · validated civic_curation pubmed
Trastuzumab emtansine for HER2-positive advanced breast cancer.

Showing 126–150 of 916 publications

← Previous
1
…
5
6
7
…
37
Next →

· N Engl J Med · 2012 · PMID 23020162 · validated civic_curation pubmed

PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis.

· Oncotarget · 2016 · PMID 26918451 · validated civic_curation pubmed

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.

· Lancet · 2016 · PMID 26970723 · validated civic_curation pubmed

Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.

· Lancet Oncol · 2016 · PMID 26973324 · validated civic_curation pubmed

Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.

· Ann Oncol · 2014 · PMID 24478318 · validated civic_curation pubmed

Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014.

· J Clin Oncol · 2016 · PMID 27022118 · validated civic_curation pubmed

Ceritinib in ALK-rearranged non-small-cell lung cancer.

· N Engl J Med · 2014 · PMID 24670165 · validated civic_curation pubmed

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.

· Lancet Oncol · 2014 · PMID 25153538 · validated civic_curation pubmed

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.

· Nat Med · 2012 · PMID 22426421 · validated civic_curation pubmed

Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.

· J Clin Oncol · 2016 · PMID 27091708 · validated civic_curation pubmed

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

· N Engl J Med · 2012 · PMID 22149875 · validated civic_curation pubmed

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

· Lancet · 2012 · PMID 22257673 · validated civic_curation pubmed

Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors.

· Cancer Res · 2013 · PMID 23204226 · validated civic_curation pubmed

Integrative clinical genomics of advanced prostate cancer.

· Cell · 2015 · PMID 26000489 · validated cbioportal_study pubmed

The AXL receptor tyrosine kinase is associated with adverse prognosis and distant metastasis in esophageal squamous cell carcinoma.

· Oncotarget · 2016 · PMID 27172793 · validated civic_curation pubmed

Elevated Serum Gas6 Is a Novel Prognostic Biomarker in Patients with Oral Squamous Cell Carcinoma.

· PLoS One · 2015 · PMID 26207647 · validated civic_curation pubmed

Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas.

· Cancer · 2013 · PMID 22810899 · validated civic_curation pubmed

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.

· Lancet Oncol · 2016 · PMID 27083334 · validated civic_curation pubmed

MTHFR c.677C>T Inhibits Cell Proliferation and Decreases Prostate Cancer Susceptibility in the Han Chinese Population in Shanghai.

· Sci Rep · 2016 · PMID 27819322 · validated civic_curation pubmed